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Plain English summary
Breast cancer is a diverse and varied disease. Recent research has shown that the collection of multiple biopsies before
surgery can help researchers determine how the cancer is responding to treatment and can predict for long-term
outcomes. However biopsies can be uncomfortable, and sometimes clinicians and research teams in hospitals may be
reluctant to offer clinical trials requiring several biopsies to patients who have been recently diagnosed with breast
cancer. The Institute of Cancer Research Clinical Trials and Statistics Unit (ICR-CTSU) oversees a large number of breast
cancer clinical trials where multiple biopsies are required. ICR-CTSU recognises that patient advocates (patients who have
previously had, or cared for someone with, cancer) are key members of the trial design group and should be involved in
the clinical trial throughout its lifespan. Patient advocates can provide reassurance regarding the acceptability of trial
designs involving multiple biopsies from a patient perspective. This paper summarises patient advocate involvement in
ICR-CTSU breast cancer trials activity and how this has benefited our research.
Abstract
The importance of collecting tissue samples in breast cancer has become increasingly recognised, as the diversity of the
disease has become better known. It has been documented in recent research that tumours may change in response to
treatment prior to surgery (the neoadjuvant treatment setting). The collection of sequential biopsies over time can
identify changes within tumours and potentially predict how the tumour may respond to certain treatments. However,
the acceptability of multiple biopsies amongst patients, clinicians and other research staff in hospitals is variable and
recruitment into clinical trials requiring multiple biopsies may be challenging.
The Institute of Cancer Research Clinical Trials and Statistics Unit (ICR-CTSU) is responsible for a portfolio of breast cancer
trials where multiple biopsies are key to the trial design. Patient advocate involvement has been essential in helping us to
design and deliver complex and innovative cancer trials which require multiple invasive tissue biopsies, often without any
direct benefit to the trial participants. The views expressed by patient advocates involved in ICR-CTSU trials supports the
published evidence that patients are willing to donate additional tissue for research and that clinicians’ concerns about
approaching patients for trials involving multiple biopsies are often unfounded.
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Patient advocate involvement in ICR-CTSU trials activity takes various forms, from membership on protocol development
groups and trial management groups, attendance at focus groups and forums, and presentations at trial development
and launch meetings. This involvement has provided reassurance to research teams within the NHS and research ethics
committees of the importance and acceptability of our trials from a patient perspective. Patient advocate involvement
throughout the lifetime of our trials ensures that the patient remains central to our research considerations.
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Background
In recent years, breast cancer has been recognised as a di-
verse and varied disease consisting of many different sub-
types [1–3]. Collecting a tissue sample (or biopsy) from a
patient is not only essential for confirmation of the diagno-
sis of breast cancer but also has the potential to define the
breast cancer subtype in order to inform treatment choices.
This is achieved by the identification of mutations (changes
to normal genetic information) that are present in the
tumour tissue sample. An example of this is the established
use of aromatase inhibitor therapy in the treatment of post-
menopausal women with oestrogen receptor positive breast
cancer. Aromatase inhibitors work by blocking the enzyme
aromatase, which turns the hormone androgen into small
amounts of oestrogen in the body. This means that less
oestrogen is available to stimulate the growth of hormone
receptor positive breast cancer cells.
The pre-surgical (neoadjuvant) treatment setting is in-
creasingly being used to provide early evidence of the
clinical activity of new treatments. In particular the as-
sessment of tumour tissue obtained during neoadjuvant
treatment from biopsies taken prior to surgery (i.e. while
the tumour remains ‘in situ’) can aid the identification of
biological markers, which provide a measurable indicator
of response and resistance to treatment. The biological
analysis of sequential biopsies obtained before, during
and after treatment can reveal how the cancer changes
over time and responds to the treatment. Therefore,
obtaining additional breast cancer tissue during treat-
ment has become an integral component in breast can-
cer research [4]. Knowing which patient population may
be responsive to treatment and which biological markers
may indicate resistance has the potential to reduce the
risk of patient exposure to treatment that is unlikely to
be of benefit, and increase the likelihood of patient ex-
posure to active treatment.
Undergoing a biopsy is an invasive procedure which
can result in additional discomfort and inconvenience
for the patient and can be technically challenging due to
the site of the disease. One of the main challenges faced
in the collection of multiple tissue biopsies is the per-
ception of clinicians that patients may not wish to be
approached for the additional biopsies, or they may not
want to subject patients to additional procedures that
would not be routinely performed as part of standard of
care. The reasons cited for not wanting to approach pa-
tients for additional biopsies include the risk associated
with the biopsy procedure, the pain or discomfort of a
biopsy and the inconvenience to patients [4]. Whilst
studies have shown that patients are willing to provide
research biopsies even when there is no direct benefit to
them [5–9], treating clinicians and other research staff
may remain reluctant due to perceived ideas of what is
acceptable.
Ethical concerns have also been raised about the col-
lection of research biopsies that will not directly benefit
the patient [9–11]. The risks associated with taking re-
search biopsies have been shown to be more acceptable
to patients than research ethics committees (RECs) who
may consider that the benefits of acquiring additional
tissue from trial participants purely for research may not
outweigh the risks [8, 9]. The importance of well written
patient information sheets that clearly describe the risks
and lack of direct benefit associated with research biop-
sies is well documented [12, 13].
Involving patient advocates in the concept develop-
ment, design and conduct of a clinical trial is important
[14–16], particularly in trials perceived as challenging
for the patient such as those requiring multiple biopsies.
The importance of patient advocate involvement
throughout the whole clinical trials process has long
been recognised by ICR-CTSU, a clinical trials unit
based in London that coordinates national and inter-
national phase II and III clinical trials with a particular
focus on breast cancer. ICR-CTSU has had close links to
several patient advocate groups for several years. Their
input has been crucial in developing participant infor-
mation materials that effectively describe the research
and the associated risks and benefits in an accessible
language that addresses the recognised concerns of pa-
tients with a cancer diagnosis being required to provide
multiple biopsies. They have also provided reassurance
to clinicians, research nurses and RECs on the accept-
ability of the collection of multiple biopsies from a pa-
tients’ perspective.
Patient advocates review and advise on all ICR-CTSU tri-
als, and there is routinely at least one patient advocate mem-
ber on the trial management group (a multidisciplinary
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group responsible for day to day oversight of the trial) for
each trial. This ensures that patient advocates have ongoing
oversight of the clinical trials and are able to give recommen-
dations and advice throughout the lifespan of the trial.
In this article we discuss the processes undertaken by
ICR-CTSU to optimise patient advocate engagement
across a number of our trials requiring the collection of
multiple biopsies and how this has ensured successful
implementation and delivery of our research.
Main text
Change in the proliferation marker Ki67 (a marker of a
rapid increase in cell numbers as measured on tumour tis-
sue) has been shown to be predictive of response to treat-
ment with aromatase inhibitors and can be used as an
indicator of risk of breast cancer occurring again (recur-
rence). Patients in the Immediate Preoperative Anastrozole,
Tamoxifen, or Combined with Tamoxifen (IMPACT) trial
[17, 18], conducted by colleagues at the Royal Marsden
Hospital, had oestrogen receptor positive early breast can-
cer and were randomised to receive aromatase inhibitor
therapies (either anastrozole alone, tamoxifen alone or ana-
strozole and tamoxifen in combination). Patients had biop-
sies taken at baseline, at 2 weeks after starting treatment
and at surgery (approximately 12 weeks after starting treat-
ment). The trial recruited 330 patients from 1997 to 2002,
and patients were followed up for several years. Data from
the sequential biopsies showed that short-term changes in
Ki67 may be able to predict disease outcomes.
On the basis of results from the IMPACT trial Ki67
has since been used as the primary efficacy end point
providing the potential to use short-term molecular
markers to predict long-term outcome in clinical trials
to allow effective treatments to reach patients more rap-
idly than waiting for long-term measures [19].
The POETIC trial
Following on from the IMPACT trial, the ICR-CTSU in
collaboration with the Royal Marsden Hospital, designed
the POETIC (Perioperative Endocrine Therapy - Indivi-
dualising Care, ISRCTN: 63882543) trial [20], a rando-
mised controlled trial investigating aromatase inhibitor
therapy in oestrogen positive early breast cancer prior to
and after surgery (the perioperative treatment setting).
The trial design required a research biopsy taken at diag-
nosis with a subsequent biopsy after 14 days treatment
with an aromatase inhibitor prior to definitive surgery
for assessment of Ki67 expression. Concerns were raised
about the concept of taking invasive research biopsies in
this relatively low risk patient population and how this
would be viewed by patients, their treating clinicians
and breast care nurses so involvement of patient advo-
cates was essential.
Patient advocates were involved in the trial design
from the outset with an extensive consultation process
being undertaken across a number of patient groups.
They were consulted on the fact that research tissue col-
lected at diagnosis may be provided by patients who
subsequently turned out to be ineligible for trial entry,
and that collecting research tissue at that time point
would allow little time for patients to consider whether
they wanted to donate tissue for research purposes. The
patient advocates provided reassurance that requesting
additional samples from the patient was acceptable pro-
viding the collection process was led by a skilled team,
the rationale for collecting the additional tissue was
clearly explained to the patient and donated samples
were utilised appropriately. They recommended that
extra tissue for research at diagnosis was collected at the
same time as the routine core biopsy, and not after diag-
nosis was confirmed. They also preferred any tissue
taken to be used for research wherever possible. This
provided valuable insight to assist communications with
the REC about the proposed research [16].
Patient advocates advised on the content of the patient
information sheets for the trial to ensure that the re-
search rationale, procedures and risks were fully ex-
plained and in an accessible language. A patient
advocate was a member of the protocol development
group and, once the trial was launched, a member of the
trial management group, providing advice throughout
the lifetime of the trial. Once launched, the trial met
with some reluctance, mainly from breast cancer nurses,
about approaching patients for participation in the trial.
Intervention from patient advocates via teleconferences
and newsletters conveyed the message that professionals
should not avoid discussing participation with potential
patients at the time of diagnosis due to concern about
adding stress, as this denies patient choice.
Despite the fact that patients had only recently re-
ceived their diagnosis, willingness to undergo additional
procedures and consider clinical trial participation was
high in POETIC and recruitment into the trial remained
on target. POETIC recruited 4486 patients between
2008 and 2014 and provides the largest multi-centre
series of women in whom centrally assessed Ki67 has
been correlated with classic clinical and pathological
measures of response. When the paired research biopsies
from each patient were compared, 29% of patients were
found to have mutations present in only one of their
two biopsies [21]. POETIC showed that for a substantial
group of patients, a single biopsy would have missed po-
tentially important mutations that may have influenced
the treatment options for the patient. The variation in
the mutations identified between the paired biopsies
may be due to the genetic differences between the differ-
ent areas of the tumour that were sampled but also may
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be due to changes to the tumour cells in response to
treatment given. Irrespective of the reason, this finding
led the POETIC investigators to conclude that multiple
biopsies are essential for confident mutational profiling
of oestrogen receptor positive breast cancer. POETIC
demonstrated that patients are willing to discuss and
consider clinical trials which request additional biopsies
whilst they are coming to terms with their diagnosis. It
also shows that education regarding the value and pur-
pose of the collection of multiple biopsies is essential for
both clinicians and patients.
The PALLET trial
Subsequent to POETIC, ICR-CTSU in collaboration with
colleagues at the Royal Marsden Hospital, designed the PAL-
LET trial (An assessment of the biological and clinical effects
of palbociclib with letrozole in the neoadjuvant treatment of
ER+ primary breast cancer, ISRCTN: 31243262). PALLET is
a randomised phase II trial in early breast cancer aiming to
investigate whether the addition of palbociclib (a targeted
drug that blocks CDK4/6 proteins involved in cell division)
to letrozole (an aromatase inhibitor) in the neoadjuvant set-
ting (prior to surgery) can reduce tumour size and assess the
effect of treatment on the reduction of tumour cell prolifera-
tion by measuring Ki67 at multiple time points. The assess-
ment of treatment effect required participants consent to
provide a biopsy at the time of trial entry, and then at 2 weeks
and 14 weeks after trial entry. Up to 4 samples were taken
using a core needle biopsy at each of the 3 time points.
Based on our experiences with POETIC it was recognised
that clinicians and breast nurses may consider the additional
required biopsy procedures too onerous for patients and
may not approach patients for the trial, so involvement of
the patient advocates from the outset was crucial.
Patient advocates from Independent Cancer Patients
Voice (ICPV), who had contributed so positively to
POETIC, and from the Royal Marsden Patient and
Carers Research Review Panel were approached for col-
laboration and involvement in the PALLET trial. The pa-
tient advocates were involved during all stages of the
trial including conception and trial launch and have an
ongoing role as members of the trial management group.
During the development and set-up of PALLET, the pa-
tient advocates advised that patients would consider en-
tering the trial provided the rationale for the multiple
biopsies was clear in the patient information documenta-
tion and there was detailed information regarding the bi-
opsy process, including potential risks and post-biopsy
care. The patient advocates advised that patients often
felt reassured by having additional investigations for re-
search as part of their participation in a clinical trial,
provided these were clearly explained upfront and that
patients commonly felt better informed of their breast
cancer disease as a result of involvement in clinical trials.
The PALLET patient information sheet was reviewed by
the patient advocates prior to submission to the REC to
ensure all relevant and useful information was included
for the committee to make an informed assessment of
the benefits and risks associated with the trial. One con-
cern raised by the REC which had previously been raised
by the patient advocates was around the potential risk of
seeding (spread of tumour cells into the blood or other
tissue) as a result of having a biopsy. The lead investiga-
tor for the trial was able to provide reassurance to the
patient advocates about the minimal risks of seeding
which the patient advocates found acceptable. This in
turn provided reassurance to the REC.
In order to minimise the potential impact that any
pre-conceptions around patient acceptance may have
had on the rate of recruitment into the trial, patient ad-
vocates from ICPV gave a presentation at the PALLET
trial launch meeting. They were able to draw on their
experiences from the POETIC trial, particularly the con-
sultation process that had taken place across a number
of patient advocate groups around the acceptability of
research biopsies from a patient perspective, and were
able to provide reassurance the national investigators
and breast cancer research nurses in attendance. An out-
line of the points raised by the patient advocates at the
trial launch meeting is summarised in Table 1.
Twelve months after opening the first site to the PAL-
LET trial, the recruitment rate was lower than expected
for a variety of reasons ranging from logistical issues at
sites to insufficient numbers of patients being
approached for the trial. It became apparent that a major
recruitment barrier was that clinicians were either not
approaching suitable patients, or not discussing the trial
adequately or at an appropriate time. For example, if cli-
nicians offered surgery dates prior to offering a clinical
trial of neoadjuvant treatment, patients often declined to
take part as they didn’t want to ‘delay’ their surgery by
having the neoadjuvant treatment. It was observed that
not approaching patients for the trial had a greater im-
pact on recruitment than patients declining due to the
requirement for multiple research biopsies. In response
to this, a teleconference was arranged for the clinicians
and research nurses at recruiting centres, and the PAL-
LET trial management group patient advocates led a dis-
cussion on the reasons clinicians may be reluctant to
approach patients for the trial. The patient advocates
re-iterated that it’s ok to ask patients about entering
clinical trials including those involving multiple biopsies.
They highlighted that the requirement for additional bi-
opsies tended not to discourage patients from participat-
ing in a clinical trial, provided the reason was clearly
explained and the biopsies were performed in the appro-
priate clinical setting with good post biopsy care pro-
vided. The patient advocates referred to the fact that
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clinicians often believed that patients would be deterred
from entering a trial requiring multiple research biopsies
to a much greater extent than they actually were. The
importance of offering all potential treatment options,
including clinical trials, to patients was highlighted in
order that patients can make their own informed deci-
sion about their preferred treatment choice, rather than
being limited to what their clinician thought was best
for them. Following the teleconference, the rate of re-
cruitment into PALLET improved and the trial reached
its target recruitment size within 3 years of the first site
opening.
Multiple biopsies patient advocate forum
Following on from the issues identified in POETIC and
PALLET, and to inform a number of new breast cancer
trials in development, ICR-CTSU arranged a Patient Ad-
vocate Forum to facilitate discussion between a wide
audience of patient advocates and clinical investigators
regarding the development of clinical trials requiring the
collection of multiple biopsies. Clinicians and research
nurses working in breast cancer research were invited to
attend, in addition to members from national patient
and public involvement groups including those who had
been involved in the design and conduct of POETIC and
PALLET. A number of new trial concepts requiring mul-
tiple biopsies were presented and discussed.
The patient advocates emphasised that it is important
that patients are provided with all the different treatment
options available to them, including clinical trials where
multiple biopsies are required. They reiterated that patients
should be fully informed about the trial design, the poten-
tial risks and benefits of participating in the trial and it
should be up to the patient to decide if it is a trial they
would like to participate in based on the information pro-
vided. Whilst the patient advocates did not think the re-
quirement for multiple biopsies within a trial would be a
barrier to trial entry from a patient perspective, they advised
that, where possible, researchers should ensure that any
additional biopsies are performed on the same day as other
trial assessments to minimise the need for patients to ar-
range, and pay for, additional travel. It was also noted that
there should be an adequate gap between the sequential bi-
opsies for patient recovery. Attendees reiterated that it
should be up to the patient to make a final decision on their
treatment pathway once all information has been provided
to them, re-emphasising the need for better clinician train-
ing in this area.
The forum included a brief presentation on the potential
future use of circulating tumour DNA (ctDNA) measured
in the blood. As ctDNA may contain mutations present in
the tumour that aren’t present in the patient’s normal gen-
etic information, ctDNA testing could be used as an alter-
native ‘liquid biopsy’ in order to identify the mutations
present in the cancer and direct treatment whilst reducing
the need for an invasive tissue biopsy. The importance of
identifying a less invasive alternative to tissue biopsies is
well recognised [9, 22]. Liquid biopsies may be particularly
beneficial to reassess the mutations present when the can-
cer spreads to another part of the body (relapse, or metas-
tases) and is not easily accessible for biopsy. This is
important as clinicians are more reluctant to approach
Table 1 Patient concerns regarding trials involving multiple biopsies
Patient concern More likely to accept Less likely to accept
Comfort and safety • Accessible biopsy site
• Good post-biopsy care offered
• Collection of research tissue during
standard procedures
• Challenging biopsy site
• Post-biopsy care not explained
• Additional visits or procedures
for tissue collection
Risks and benefits • Given sufficient information about
purpose of the research and need
for biopsies
• Risks of tumour seeding explained
• Other risks, including discomfort at
biopsy site, fully explained
• Lack of direct benefit fully explained
• Research is considered ‘exciting’ –
involving and educating patients
• Research will improve outcomes
in future patients and exclude
unnecessary treatment in future
patients
• Not given sufficient information
about purpose, risks and benefits
Timing • Given adequate time to decide • Badly timed or insensitive introduction
to trial
Quality control • Clear explanation of what happens
to the samples
• Use of samples not adequately explained
History • Patients with metastatic disease
• Family history
• Previous poor experiences of research
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patients for biopsies of metastatic disease sites [4, 6, 22].
However, in order to evaluate the use of ctDNA as a
screening tool there is a need to compare liquid biopsy re-
sults with the results obtained from a tissue sample biopsy
to ensure the ctDNA screening is reliable and accurate.
Clinical trials are currently being conducted to address
this before the use of ctDNA testing could become routine
practice in the future.
Feedback from the meeting was used in initial applica-
tions to, and during discussions with, regulators and
RECs regarding the proposed trial designs that utilise
multiple tissue or liquid biopsies. Patient advocate sup-
port for these trials undoubtedly provided reassurance to
regulators and RECs regarding the importance and ac-
ceptability of these novel trial designs to patients.
Conclusions
As breast cancer treatments become more specific, or
‘personalised’, the inclusion of multiple biopsies in the
design of clinical trials is becoming more common [4, 8,
9]. The collection of multiple biopsies allows the identi-
fication of changes in the molecular profile of the dis-
ease over time and in response to treatment received.
Patients are now frequently required to consent upfront
to the collection of additional research biopsies during
trial participation. Despite patient willingness to enter
trials that require multiple biopsies [6–8, 23] concerns
exist amongst clinicians and research nurses about ap-
proaching patients due to misconceptions around pa-
tient acceptance of potentially uncomfortable and
inconvenient research procedures [4, 6, 8, 9]. Ethical
concerns around the risks of the biopsy procedure and
lack of direct benefit to the patient exist [8–12, 22]. Pa-
tient advocate involvement can help allay these concerns
and provide reassurance about the acceptability of mul-
tiple biopsies from a patient perspective.
Patient advocates have emphasised that when ap-
proaching patients about trials requiring multiple biop-
sies, it is of paramount importance to describe the
rationale behind the collection of multiple biopsies and
the associated risks. Well written patient information
sheets enable patients to make an informed assessment
of the risks and benefits; patient advocate involvement
in the development of these materials is essential to en-
sure that the information is conveyed in an accessible
and understandable format. The use of teleconferences
with participating hospitals which include involvement
of the patient advocates and patient advocate representa-
tion at trial launch meetings can help to provide hospital
staff at recruiting sites with a clearer idea as to the pa-
tient perspective on trials requiring multiple biopsies.
Further education and communication in the area of
multiple biopsies is required amongst clinicians and care
teams, to ensure patients are introduced to the trials
appropriately, sensitively, and to minimise clinicians’ dis-
comfort with the idea of obtaining sequential biopsies
from patients throughout the lifespan of a clinical trial.
The use of novel less-invasive techniques, such as liquid
biopsies, may provide a more acceptable alternative to
clinicians and patients alike in the future. Forums orga-
nised to facilitate discussion between clinicians and pa-
tient advocates can help address concerns about new
trial designs, including those involving multiple biopsies,
and new techniques, and provide an excellent learning
opportunity for all involved.
ICR-CTSU has a long history of working with patient
advocates [16] and has a strong belief that researchers
should employ a more consistent, focused approach when
involving patient advocates in the development of clinical
trials. This is now a requirement of many funders and
RECs. Well-organised patient advocate involvement can
help to increase the success of a clinical trial providing
RECs, regulators, clinicians and research nurses with re-
assurance about the acceptability of trial procedures, ul-
timately ensuring successful recruitment into the trial. We
recommend that patient advocates are involved from the
trial design stage and throughout the lifetime of the trial
through membership on protocol development and trial
management groups. Feedback from researchers to patient
advocate groups is also important. Our experience is that
patient advocates appreciate understanding how their in-
put has benefitted the trial and are more likely to engage
in the development of future trials as a result.
Patient advocate groups are a key link between re-
searchers and the general public whose consent to partici-
pation in clinical trials is crucial to their success. The need
for patients to be informed of all options and the reasons
behind trial requirements, such as multiple biopsies, is es-
sential and should not be overlooked. The involvement of
patient advocates throughout clinical trials from design to
publication is essential and should be taken into consider-
ation from the point of trial conception.
Abbreviations
ctDNA: Circulating tumour DNA; ICPV: Independent Cancer Patients’ Voice;
ICR-CTSU: Institute of Cancer Research Clinical Trials and Statistics Unit;
IMPACT: Immediate Preoperative Anastrozole, Tamoxifen, or Combined with
Tamoxifen trial; NIHR: National Institute for Health Research; PALLET: An
assessment of the biological and clinical effects of palbociclib with letrozole
in the neoadjuvant treatment of ER+ primary breast cancer;
POETIC: Perioperative Endocrine Therapy - Individualising Care trial;
REC: Research Ethics Committee
Acknowledgements
The co-authors of this paper would like to thank all patients and staff at
recruiting centres that were involved in the clinical trials referred to within
this paper. We would also like to acknowledge the PALLET TMG for their
consent to use the trial as an example within this paper and for reviewing
the paper.
Funding
The Institute of Cancer Research Clinical Trials and Statistics Unit (ICR-CTSU)
is supported by a core programme grant (grant number C1491/A15955)
Batten et al. Research Involvement and Engagement  (2018) 4:22 Page 6 of 7
from Cancer Research UK (LB, IB, LM, JH, ME, SM, MH, RT, JMB) and a Clinical
Trial Fellowship (C1491/A8895: IB). We acknowledge NHS funding to the
NIHR Biomedical Research Centre at The Royal Marsden and the ICR. The
funders had no role in writing the manuscript.
Authors’ contributions
All authors were involved in the drafting and revising of this manuscript. All
authors read and approved the final manuscript.
Ethics approval and consent to participate
All clinical trials mentioned by name in this paper had full ethical review and
approval, all patients that took part with the studies consented to do so.
Further details: IMPACT was approved first by a national multicenter research
ethical committee and subsequently by individual local research ethics
committees; POETIC – South East Research Ethics Committee, 08/H1102/37;
PALLET – London Fulham Research Ethics Committee, 14/LO/1291.
Competing interests
The authors declare that they have no competing interests.
Publisher’s Note
Springer Nature remains neutral with regard to jurisdictional claims in
published maps and institutional affiliations.
Author details
1Division of Clinical Studies, The Institute of Cancer Research Clinical Trials
and Statistics Unit, Sir Richard Doll Building, 15 Cotswold Road, Sutton,
London SM2 5NG, UK. 2National Cancer Research Institute, Angel Building,
407, St John Street, Clerkenwell, London EC1V 4AD, UK. 3Independent Cancer
Patients Voice, 17 Woodbridge St, Clerkenwell, London EC1R 0LL, UK.
Received: 9 June 2017 Accepted: 3 July 2018
References
1. Andre F, Bachelot T, Commo F, Campone M, Arnedos M, Dieras V, Lacroix-
Triki M, Lacroix L, Cohen P, Gentien D, et al. Comparative genomic
hybridisation array and DNA sequencing to direct treatment of metastatic
breast cancer: a multicentre, prospective trial (SAFIR01/UNICANCER). Lancet
Oncol. 2014;15(3):267–74.
2. Curtis C, Shah SP, Chin SF, Turashvili G, Rueda OM, Dunning MJ, Speed D,
Lynch AG, Samarajiwa S, Yuan Y, et al. The genomic and transcriptomic
architecture of 2,000 breast tumours reveals novel subgroups. Nature. 2012;
486(7403):346–52.
3. Shah SP, Roth A, Goya R, Oloumi A, Ha G, Zhao Y, Turashvili G, Ding J, Tse K,
Haffari G, et al. The clonal and mutational evolution spectrum of primary
triple-negative breast cancers. Nature. 2012;486(7403):395–9.
4. Seah DS, Scott S, Guo H, et al. Variation in the attitudes of medical
oncologists toward research biopsies in patients with metastatic breast
cancer. Oncologist. 2015;20:992–1000.
5. Naim F, Ballinger R, Rombach I, Hadjiminas DJ, Al-Mufti R, Hogben RK,
McLauchlan R, Palmieri C, Cleator SJ. Patient attitudes towards undergoing
additional breast biopsy for research. Breast. 2013;22(5):850–5.
6. Lohrisch C, Francl M, Sun S, et al. Willingness of breast cancer patients to
undergo biopsy and breast cancer clinicians’ practices around seeking
biopsy at the time of breast cancer relapse. Breast Cancer Res Treat. 2018;
168:221.
7. Moorcraft SY, Marriott C, Peckitt C, Cunningham D, Chau I, Starling N,
Watkins D, Rao S. Patients’ willingness to participate in clinical trials and
their views on aspects of cancer research: results of a prospective patient
survey. Trials. 2016;17:17.
8. Agulnik M, Oza AM, Pond GR, et al. Impact and perceptions of mandatory
tumor biopsies for correlative studies in clinical trials of novel anticancer
agents. J Clin Oncol. 2006;24:4801–7.
9. Saggese M, Dua D, Simmons E, Lemech C, Arkenau H. Research biopsies in
the context of early phase oncology studies: clinical and ethical
considerations. Oncol Rev. 2013;7(1):e5.
10. Helft PR, Daugherty CK. Are we taking without giving in return? The ethics
of research-related biopsies and the benefits of clinical trial participation. J
Clin Oncol. 2006;24:4793–5.
11. Peppercorn J, Shapira I, Collyar D, et al. Ethics of mandatory research biopsy
for correlative end points within clinical trials in oncology. J Clin Oncol.
2010;28:2635–40.
12. Overman MJ, Modak J, Kopetz S, et al. Use of research biopsies in clinical trials:
are risks and benefits adequately discussed? J Clin Oncol. 2013;31:17–22.
13. Kodish E, Stocking C, Ratain MJ, et al. Ethical issues in phase I oncology
research: a comparison of investigators and institutional review board
chairpersons. J Clin Oncol. 1992;10:1810–6.
14. Marsden J, Bradburn J. Patient and clinician collaboration in the design of a
national randomized breast cancer trial. Health Expect. 2004;7:6–17.
15. Katz ML, Archer LE, Peppercorn JM, Kereakoglow S, Collyar DE, Burstein HJ,
Schilsky RL, Partridge AH. Patient advocates' role in clinical trials. Cancer.
2012;118:4801–5.
16. Gasson S, Bliss J, Jamal-Hanjani M, Krebs M, Swanton C, Wilcox M. The value
of patient and public involvement in trial design and development. Clin
Oncol. 2015;27(12):747–9.
17. Dowsett M, Smith IE, Ebbs SR, Dixon JM, Skene A, Griffith C, Boeddinghaus I,
Salter J, Detre S, Hills M, et al. Short-term changes in Ki-67 during
neoadjuvant treatment of primary breast cancer with anastrozole or
tamoxifen alone or combined correlate with recurrence-free survival. Clin
Cancer Res. 2005;11(2 Pt 2):951s–8s.
18. Smith IE, Dowsett M, Ebbs SR, Dixon JM, Skene A, Blohmer JU, Ashley SE,
Francis S, Boeddinghaus I, Walsh G, et al. Neoadjuvant treatment of
postmenopausal breast cancer with anastrozole, tamoxifen, or both in
combination: the immediate preoperative Anastrozole, tamoxifen, or
combined with tamoxifen (IMPACT) multicenter double-blind randomized
trial. J Clin Oncol. 2005;23(22):5108–16.
19. Smith IE, Walsh G, Skene A, Llombart A, Mayordomo JI, Detre S, Salter J,
Clark E, Magill P, Dowsett M. A phase II placebo-controlled trial of
neoadjuvant anastrozole alone or with gefitinib in early breast cancer. J Clin
Oncol. 2007;25(25):3816–22.
20. Dowsett M, Nielsen TO, A'Hern R, Bartlett J, Coombes RC, Cuzick J, Ellis M,
Henry NL, Hugh JC, Lively T, et al. Assessment of Ki67 in breast cancer:
recommendations from the international Ki67 in breast Cancer working
group. J Natl Cancer Inst. 2011;103(22):1656–64.
21. Gellert P, Segal CV, Gao Q, Lopez-Knowles E, Martin LA, Dodson A, Li T,
Miller CA, Lu C, Mardis ER, et al. Impact of mutational profiles on response
of primary oestrogen receptor-positive breast cancers to oestrogen
deprivation. Nat Commun. 2016;7:13294.
22. Brown A, Wendler D, Camphausen K, et al. Performing nondiagnostic
research biopsies in irradiated tissue: a review of scientific, clinical, and
ethical considerations. J Clin Oncol. 2008;26:3987–94.
23. Vaz-Luis I, Zeghibe CA, Frank ES, et al. Prospective clinical experience with
research biopsies in breast cancer patients. Breast Cancer Res Treat. 2013;
142:203–9.
Batten et al. Research Involvement and Engagement  (2018) 4:22 Page 7 of 7
